
|Videos|January 13, 2017
An Overview of the TnAcity Trial in TNBC
Author(s)Denise Yardley, MD
Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the phase II tnAcity trial in triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
5








































